Abstract
Objective: To evaluate the effect and safety of neoadjuvant chemotherapy combined with PA-MSHA injection for breast cancer patients. Methods: An open randomized controlled clinical trial was conducted. Fourty patients with breast cancer were randomly assigned to neoadjuvant chemotherapy group (the control group, n=20) and neoadjuvant chemotherapy combined with PA-MSHA injection group (the experiment group, n=20). The evaluation of therapeutic effect was carried out when the treatment was completed. Karnofsky score was recorded before and after therapy. Venous blood was drawn before and after therapy and immune function (IFN-γ, IL-2, IL-4, and IL-10) and other indicators (Caspase-3, VEGF, MMP-2 and MMP-9) were measured by double antibody ELISA test. Adverse effects of PA-MSHA during therapy were observed and recorded. Results: The overall response rate (RR) in the experiment group was significantly higher than that in the control group (P0.05). No significant difference was found in the pathologic complete remission (pCR) between the experiment group and the control group (P0.05). In the experimental group, pCR was significantly different before and after therapy (P0.01). The score in the experimental group was significantly higher than that in the control group after therapy (P0.01). With the treatment of chemotherapy and PA-MSHA injection, IFN-γ and IL-2 levels were significantly higher while IL-4 and IL-10 levels were significantly lower in the experiment group (P0.05). A significant increase in serum Caspase-3 and a significant de- crease in serum VEGF, MMP-2 and MMP-9 (P0.05) after therapy were also observed in the experimental group. The level of serum MMP-9 was decreased significantly (P0.05) after therapy in the control group.Conclusion: Neoadjuvant chemotherapy combined with PA-MSHA injection can significantly improve the RR of breast cancer patients, enhance their cellular immune function, induce the apoptosis and restrain the metastasis of breast cancer cells. The PA-MSHA has been proved to be an ideal supplementary therapy for breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
